D. E. Shaw & Co., Inc. Abeona Therapeutics Inc. Transaction History
D. E. Shaw & Co., Inc.
- $156 Billion
- Q3 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Abeona Therapeutics Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 126,384 shares of ABEO stock, worth $562,408. This represents 0.0% of its overall portfolio holdings.
Number of Shares
126,384Holding current value
$562,408% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ABEO
# of Institutions
105Shares Held
32.7MCall Options Held
1.34MPut Options Held
286K-
Nantahala Capital Management, LLC New Canaan, CT4.56MShares$20.3 Million0.98% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.05MShares$13.6 Million0.03% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.68MShares$11.9 Million0.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.6MShares$11.6 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA1.84MShares$8.2 Million1.55% of portfolio
About ABEONA THERAPEUTICS INC.
- Ticker ABEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,950,380
- Market Cap $26.5M
- Description
- Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...